Geron Corporation

NASDAQ:GERN

Biotechnology

Healthcare
$0.99 +4.07%

+$0.05 today

Market cap
$638.38M
Beta
0.60
P/E (TTM)
-12.3
EPS (TTM)
-$0.10
52W Low $1.04High $2.01

Volume 34.97M

Average 16.28M

GERN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Geron CorporationNASDAQ: GERN

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 96.7%

Gross margin was 96.7% in Q1 FY2026, down 0.2 pp from a year earlier. On a trailing-twelve-month basis it was 86.6%, down 11.3 pp year over year. Over 3 fiscal years it narrowed by 2.6 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
96.7%-0.5 pp QoQ
Last fiscal yearDec 2025
97.4%-0.9 pp YoY
LTMMar 2026
86.6%-11.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.2 pp——
1 year-0.9 pp——
3 years-2.6 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
97.4%
Year-over-year change
-0.9pp

Gross Margin vs competitors

How GERN compares with its peers on the latest reported figures

  • GERN's LTM Mar 2026 gross margin of 86.6% is the lowest of the 5 companies compared; the peer median is 93.0%.
  • Its year-over-year change of -11.3 pp is the 3rd highest of 4, against a peer median of -0.3 pp.
  • Over three fiscal years its change of -2.6 pp compares with a peer median of -3.2 pp.
GERN Competitors Peer median
Gross Margin for GERN and competitors
Company Period LTM level YoY 3-year change
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026101.1% —+0.0 pp
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202693.4% +3.7 pp-5.2 pp
INCYIncyte CorporationLTM Jun 202692.6% -0.3 pp-1.1 pp
IPSCCentury Therapeutics, Inc.FY202588.0% -12.0 pp-12.0 pp
GERNGeron CorporationLTM Mar 202686.6% -11.3 pp-2.6 pp
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025— ——
SLSSELLAS Life Sciences Group, Inc.FY2025— ——
DMRADamora Therapeutics, Inc.FY2025— ——
Peer median (excluding GERN) 93.0%-0.3 pp-3.2 pp

Competitors are the stored peer set for GERN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.39M596K237K76.99M183.88M
Cost of Revenue0001.26M4.75M
Gross Profit1.39M596K237K75.74M179.14M
Gross Margin100.0%100.0%100.0%98.4%97.4%
Research & Development85.73M95.52M125.05M103.74M73.72M
Selling, General & Admin29.67M43.63M69.14M145.73M159.26M
Operating Expenses115.39M139.15M194.18M249.47M232.97M
Depreciation & Amortization783K868K1.03M1.22M1.2M
EBITDA(111.59M)(134.15M)(174.78M)(154.85M)(51.92M)
EBITDA Margin-8010.7%-22508.6%-73747.7%-201.1%-28.2%
Operating Income(114M)(138.55M)(193.94M)(173.73M)(53.84M)
Operating Margin-8183.7%-23246.6%-81832.9%-225.6%-29.3%
Interest Income527K2.53M18.15M19.61M18.12M
Interest Expense3.74M6.88M8.31M18.5M32.66M
Other Income / Expenses(2.11M)(3.35M)9.82M(840K)(31.95M)
Income Before Tax(116.11M)(141.9M)(184.13M)(174.57M)(85.78M)
Pre-Tax Margin-8335.4%-23808.9%-77690.7%-226.7%-46.7%
Income Tax Expense00000
Net Income(116.11M)(141.9M)(184.13M)(174.57M)(85.78M)
Net Margin-8335.4%-23808.9%-77690.7%-226.7%-46.7%
EPS (Basic)(0.37)(0.37)(0.32)(0.27)(0.13)
EPS (Diluted)(0.37)(0.37)(0.32)(0.27)(0.13)
Weighted Avg Shares327.63M380.78M570.65M646.03M666.66M
Weighted Avg Shares (Diluted)327.63M380.78M570.65M646.03M666.66M

Geron Corporation

NASDAQ:GERN

Intrinsic Alpha fair value

Locked

Current Price

$0.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.